Mohit Manrao: Bridging the gap between academic learning and real-world industry application

Mohit Manrao posted on LinkedIn:

“GIVE BACK DAY – Bridging the gap between academic learning and real-world industry application.

This week AstraZeneca welcomed post-grad students from eight local universities at our Gaithersburg Campus, giving over 70 students the opportunity to gain real-world experience to supplement their studies. Students participated in a variety of workshops, including speed networking, landing the job, the business of pharma and more.

This event marked a significant step towards our health equity and IandD goals. AstraZeneca’s commitment to nurturing a diverse talent pool is essential. By tapping into our community and providing these opportunities, AstraZeneca is not only supporting the development of future leaders but also ensuring that our workforce reflects the diversity of the communities we both work within and serve.

Let’s continue our efforts to foster an inclusive and equitable environment, particularly for underserved and underrepresented populations. Thank you to Laverah Olukune, Épiphanie Yohou and the entire planning committee for the first of many events of its kind!”

Karen Knudsen shared this post adding:

“What a fantastic idea. Well done Mohit Manrao and AstraZeneca!!”

Mohit Manrao is the SVP and Head of US Oncology at AstraZeneca and President of the AstraZeneca Foundation, where he leads community grant programs. As Executive Sponsor of AstraZeneca’s US Health Equity Initiative, he focuses on reducing healthcare disparities. He also serves as a Board Member of the National Pharmaceutical Council.

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR).

She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.